Figure 5
From: Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
CIK activity in ovarian cancer PDX. (A,B) The antitumor activity of patient-derived CIK was confirmed in vivo within a patient-derived high grade serous (chemo-naïve) ovarian cancer PDX model. The antitumor activity was evaluated by measuring variations in the tumor-glucose uptake in vivo. Representative pictures of tumor-glucose uptake for each mice and cumulative analysis are reported and compared with untreated controls.
